查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
乾癬治療的全球市場:產業分析，規模，佔有率，成長，趨勢，預測(2022年～2031年)
市場調查報告書
商品編碼
1110378

乾癬治療的全球市場:產業分析，規模，佔有率，成長，趨勢，預測(2022年～2031年)

Psoriasis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日期: | 出版商: Transparency Market Research | 英文 200 Pages | 商品交期: 2-10個工作天內

價格

本報告提供全球乾癬治療市場相關調查分析，市場促進因素和阻礙因素，COVID-19影響，各市場區隔的分析與預測，各地區分析，企業簡介等資訊。

目錄

第1章 序文

第2章 前提與調查手法

第3章 摘要整理:全球乾癬治療市場

第4章 市場概要

  • 簡介
    • 醫藥品分類定義
    • 產業的演進/開發
  • 概要
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 機會
  • 全球乾癬治療市場分析與預測(2017年～2031年)
    • 市場收益預測
    • 市場規模/出貨台數預測
  • 波特的五力分析

第5章 主要洞察

  • 法規情境:各地區/主要國家
  • 開發平台分析
  • 主要的合併和收購
  • COVID-19影響分析

第6章 全球乾癬治療市場分析與預測:各醫藥品分類

  • 簡介和定義
  • 主要調查結果/開發
  • 市場價值預測:各醫藥品分類(2017年～2031年)
    • TNF抑制劑
    • 白細胞介素抑制劑
    • 維他命D類似體
    • 皮質類固醇
    • 其他
  • 市場魅力分析:各醫藥品分類

第7章 全球乾癬治療市場分析與預測:各給藥途徑

  • 簡介和定義
  • 主要調查結果/開發
  • 市場價值預測:各給藥途徑(2017年～2031年)
    • 口服
    • 非口服
    • 局部
  • 市場魅力分析:各給藥途徑

第8章 全球乾癬治療市場分析與預測:各流通管道

  • 簡介和定義
  • 主要調查結果/開發
  • 市場價值預測:各流通管道(2017年～2031年)
    • 院內藥局
    • 零售藥局
    • 其他
  • 市場魅力分析:各流通管道

第9章 全球乾癬治療市場分析與預測:各地區

  • 主要調查結果
  • 市場價值預測:各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東、非洲
  • 市場魅力分析:各地區

第10章 北美的乾癬治療市場分析與預測

  • 簡介
    • 主要調查結果
  • 市場價值預測:各醫藥品分類(2017年～2031年)
    • TNF抑制劑
    • 白細胞介素抑制劑
    • 維他命D類似體
    • 皮質類固醇
    • 其他
  • 市場價值預測:各給藥途徑(2017年～2031年)
    • 口服
    • 非口服
    • 局部
  • 市場價值預測:各流通管道(2017年～2031年)
    • 院內藥局
    • 零售藥局
    • 其他
  • 市場價值預測:各國(2017年～2031年)
    • 美國
    • 加拿大
  • 市場魅力分析
    • 各醫藥品分類
    • 各給藥途徑
    • 各流通管道
    • 各國

第11章 歐洲的乾癬治療市場分析與預測

第12章 亞太地區的乾癬治療市場分析與預測

第13章 南美的乾癬治療市場分析與預測

第14章 中東、非洲的乾癬治療市場分析與預測

第15章 競爭情形

  • 市場參與企業 - 競爭矩陣(階層、各企業規模)
  • 市場佔有率分析:各企業(2021年)
  • 企業簡介
    • Amgen, Inc.
    • AstraZeneca plc
    • AbbVie, Inc.
    • Eli Lilly and Company
    • Johnson & Johnson
    • Biogen, Inc.
    • Novartis AG
    • Merck & Co., Inc.
    • Pfizer, Inc.
    • LEO Pharma A/S
    • 其他企業
Product Code: TMRGL17960

The report provides revenue of the global psoriasis treatment market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global psoriasis treatment market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the psoriasis treatment market.

The report delves into the competitive landscape of the global psoriasis treatment market. Key players operating in the global psoriasis treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global psoriasis treatment market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Psoriasis Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Drug Class Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Psoriasis Treatment Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)
    • 4.4.2. Market Volume/Unit Shipments Projections
  • 4.5. Porter's Five Force Analysis

5. Key Insights

  • 5.1. Regulatory Scenario by Region/Key Country
  • 5.2. Pipeline Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Impact Analysis

6. Global Psoriasis Treatment Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Drug Class, 2017-2031
    • 6.3.1. TNF Inhibitors
    • 6.3.2. Interleukin Inhibitors
    • 6.3.3. Vitamin D Analogs
    • 6.3.4. Corticosteroids
    • 6.3.5. Others
  • 6.4. Market Attractiveness Analysis, by Drug Class

7. Global Psoriasis Treatment Market Analysis and Forecast, by Route of Administration

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 7.3.1. Oral
    • 7.3.2. Parenteral
    • 7.3.3. Topical
  • 7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Psoriasis Treatment Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Others
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Psoriasis Treatment Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Psoriasis Treatment Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Drug Class, 2017-2031
    • 10.2.1. TNF Inhibitors
    • 10.2.2. Interleukin Inhibitors
    • 10.2.3. Vitamin D Analogs
    • 10.2.4. Corticosteroids
    • 10.2.5. Others
  • 10.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 10.3.1. Oral
    • 10.3.2. Parenteral
    • 10.3.3. Topical
  • 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Others
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Drug Class
    • 10.6.2. By Route of Administration
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Psoriasis Treatment Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Class, 2017-2031
    • 11.2.1. TNF Inhibitors
    • 11.2.2. Interleukin Inhibitors
    • 11.2.3. Vitamin D Analogs
    • 11.2.4. Corticosteroids
    • 11.2.5. Others
  • 11.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 11.3.1. Oral
    • 11.3.2. Parenteral
    • 11.3.3. Topical
  • 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Others
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Spain
    • 11.5.5. Italy
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Drug Class
    • 11.6.2. By Route of Administration
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Psoriasis Treatment Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Class, 2017-2031
    • 12.2.1. TNF Inhibitors
    • 12.2.2. Interleukin Inhibitors
    • 12.2.3. Vitamin D Analogs
    • 12.2.4. Corticosteroids
    • 12.2.5. Others
  • 12.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 12.3.1. Oral
    • 12.3.2. Parenteral
    • 12.3.3. Topical
  • 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Others
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Drug Class
    • 12.6.2. By Route of Administration
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America Psoriasis Treatment Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Class, 2017-2031
    • 13.2.1. TNF Inhibitors
    • 13.2.2. Interleukin Inhibitors
    • 13.2.3. Vitamin D Analogs
    • 13.2.4. Corticosteroids
    • 13.2.5. Others
  • 13.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 13.3.1. Oral
    • 13.3.2. Parenteral
    • 13.3.3. Topical
  • 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Others
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Drug Class
    • 13.6.2. By Route of Administration
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Psoriasis Treatment Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Drug Class, 2017-2031
    • 14.2.1. TNF Inhibitors
    • 14.2.2. Interleukin Inhibitors
    • 14.2.3. Vitamin D Analogs
    • 14.2.4. Corticosteroids
    • 14.2.5. Others
  • 14.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 14.3.1. Oral
    • 14.3.2. Parenteral
    • 14.3.3. Topical
  • 14.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Others
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Drug Class
    • 14.6.2. By Route of Administration
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (by tier and size of companies)
  • 15.2. Market Share Analysis, by Company, 2021
  • 15.3. Company Profiles
    • 15.3.1. Amgen, Inc.
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Strategic Overview
    • 15.3.2. AstraZeneca plc
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Strategic Overview
    • 15.3.3. AbbVie, Inc.
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Strategic Overview
    • 15.3.4. Eli Lilly and Company
      • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Strategic Overview
    • 15.3.5. Johnson & Johnson
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Strategic Overview
    • 15.3.6. Biogen, Inc.
      • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Strategic Overview
    • 15.3.7. Novartis AG
      • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Strategic Overview
    • 15.3.8. Merck & Co., Inc.
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Strategic Overview
    • 15.3.9. Pfizer, Inc.
      • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Strategic Overview
    • 15.3.10. LEO Pharma A/S
      • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. SWOT Analysis
      • 15.3.10.4. Strategic Overview
    • 15.3.11. Other Players

List of Table

  • Table 01: Global Psoriasis Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 02: Global Psoriasis Treatment Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 03: Global Psoriasis Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 04: Global Psoriasis Treatment Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Psoriasis Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 06: North America Psoriasis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 07: North America Psoriasis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 08: North America Psoriasis Treatment Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 09: Europe Psoriasis Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 10: Europe Psoriasis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 11: Europe Psoriasis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 12: Europe Psoriasis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 13: Asia Pacific Psoriasis Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 14: Asia Pacific Psoriasis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 15: Asia Pacific Psoriasis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 16: Asia Pacific Psoriasis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 17: Latin America Psoriasis Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 18: Latin America Psoriasis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 19: Latin America Psoriasis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 20: Latin America Psoriasis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 21: Middle East & Africa Psoriasis Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 22: Middle East & Africa Psoriasis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 23: Middle East & Africa Psoriasis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 24: Middle East & Africa Psoriasis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

List of Figures

  • Figure 01: Global Psoriasis Treatment Market Snapshot, 2021
  • Figure 02: Global Psoriasis Treatment Market Size (US$ Mn) Forecast, 2017-2031
  • Figure 04: Global Psoriasis Treatment Market Value Share, by Route of Administration, 2021
  • Figure 06: Global Psoriasis Treatment Market Value Share, by Region, 2021
  • Figure 03: Global Psoriasis Treatment Market Value Share, by Drug Class, 2021
  • Figure 05: Global Psoriasis Treatment Market Value Share, by Distribution Channel, 2021
  • Figure 07: Regulatory Approval Process - U.S.
  • Figure 08: Regulatory Approval Process - Europe
  • Figure 09: Regulatory Approval Process - Japan
  • Figure 10: Global Psoriasis Treatment Market Value Share, by Drug Class, 2021 and 2031
  • Figure 11: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by TNF Inhibitors, 2017-2031
  • Figure 12: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Interleukin Inhibitors, 2017-2031
  • Figure 13: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Vitamin D Analogs, 2017-2031
  • Figure 14: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Corticosteroids, 2017-2031
  • Figure 15: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2031
  • Figure 16: Global Psoriasis Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 17: Global Psoriasis Treatment Market Value Share, by Route of Administration, 2021 and 2031
  • Figure 18: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Oral, 2017-2031
  • Figure 19: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Parenteral, 2017-2031
  • Figure 20: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Topical, 2017-2031
  • Figure 21: Global Psoriasis Treatment Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 22: Global Psoriasis Treatment Market Value Share, by Distribution Channel, 2021 and 2031
  • Figure 23: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017-2031
  • Figure 24: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017-2031
  • Figure 25: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2031
  • Figure 26: Global Psoriasis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 27: Global Psoriasis Treatment Market Value Share, by Region, 2021 and 2031
  • Figure 28: Global Psoriasis Treatment Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 29: North America Psoriasis Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 30: North America Psoriasis Treatment Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 31: North America Psoriasis Treatment Market Value Share, by Drug Class, 2021 and 2031
  • Figure 32: North America Psoriasis Treatment Market Value Share, by Route of Administration, 2021 and 2031
  • Figure 33: North America Psoriasis Treatment Market Value Share, by Distribution Channel, 2021 and 2031
  • Figure 34: North America Psoriasis Treatment Market Value Share Analysis, by Country, 2021 and 2031
  • Figure 35: North America Psoriasis Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 36: North America Psoriasis Treatment Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 37: North America Psoriasis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 38: Europe Psoriasis Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031
  • Figure 39: Europe Psoriasis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 40: Europe Psoriasis Treatment Market Value Share, by Drug Class, 2021 and 2031
  • Figure 41: Europe Psoriasis Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 42: Europe Psoriasis Treatment Market Value Share, by Route of Administration, 2021 and 2031
  • Figure 43: Europe Psoriasis Treatment Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 44: Europe Psoriasis Treatment Market Value Share, by Distribution Channel, 2021 and 2031
  • Figure 45: Europe Psoriasis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 46: Europe Psoriasis Treatment Market Value Share, by Country/Sub-region, 2021 and 2031
  • Figure 47: Asia Pacific Psoriasis Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 48: Asia Pacific Psoriasis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 49: Asia Pacific Psoriasis Treatment Market Value Share, by Drug Class, 2021 and 2031
  • Figure 50: Asia Pacific Psoriasis Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 51: Asia Pacific Psoriasis Treatment Market Value Share, by Route of Administration, 2021 and 2031
  • Figure 52: Asia Pacific Psoriasis Treatment Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 53: Asia Pacific Psoriasis Treatment Market Value Share, by Distribution Channel, 2021 and 2031
  • Figure 54: Asia Pacific Psoriasis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 55: Asia Pacific Psoriasis Treatment Market Value Share, by Country/Sub-region, 2021 and 2031
  • Figure 56: Latin America Psoriasis Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 57: Latin America Psoriasis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 58: Latin America Psoriasis Treatment Market Value Share, by Drug Class, 2021 and 2031
  • Figure 59: Latin America Psoriasis Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 60: Latin America Psoriasis Treatment Market Value Share, by Route of Administration, 2021 and 2031
  • Figure 61: Latin America Psoriasis Treatment Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 62: Latin America Psoriasis Treatment Market Value Share, by Distribution Channel, 2021 and 2031
  • Figure 63: Latin America Psoriasis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 64: Latin America Psoriasis Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 65: Middle East & Africa Psoriasis Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 66: Middle East & Africa Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 67: Middle East & Africa Psoriasis Treatment Market Value Share, by Drug Class, 2021 and 2031
  • Figure 68: Middle East & Africa Psoriasis Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 69: Middle East & Africa Psoriasis Treatment Market Value Share, by Route of Administration, 2021 and 2031
  • Figure 70: Middle East & Africa Psoriasis Treatment Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 71: Middle East & Africa Psoriasis Treatment Market Value Share, by Distribution Channel, 2021 and 2031
  • Figure 72: Middle East & Africa Psoriasis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 73: Middle East & Africa Market Value Share, by Country/Sub-region, 2021 and 2031